scholarly journals Replacement of neutral protamine Hagedorn insulin with the long-acting insulin analogue, detemir, improves glycemic control without weight gain in basal-bolus insulin therapy in Japanese patients with type 1 diabetes

2010 ◽  
Vol 2 (1) ◽  
pp. 71-77 ◽  
Author(s):  
Taro Hayakawa ◽  
Michiyo Ishii ◽  
Megumi Watanabe ◽  
Hiroya Iwase ◽  
Asako Nishimura ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Weight Gain ◽  
Insulin Analogue ◽  
Japanese Patients ◽  
Acting Insulin ◽  
Neutral Protamine Hagedorn ◽  
Long Acting ◽  
Bolus Insulin ◽  
Basal Bolus

scholarly journals Switching from Twice-Daily Basal Insulin Injections to Once-Daily Insulin Degludec Injection for Basal-Bolus Insulin Regimen in Japanese Patients with Type 1 Diabetes: A Pilot Study

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Yuka Tosaka ◽  
Akio Kanazawa ◽  
Fuki Ikeda ◽  
Mayu Iida ◽  
Junko Sato ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Basal Insulin ◽  
Japanese Patients ◽  
Insulin Degludec ◽  
Insulin Regimen ◽  
Once Daily ◽  
Daily Insulin ◽  
Bolus Insulin ◽  
Basal Bolus

The aim of this study was to investigate the efficacy of insulin degludec used for basal-bolus insulin regimen after switching from twice-daily basal insulin in Japanese patients with type 1 diabetes mellitus. The subjects were 22 type 1 diabetes patients treated with basal-bolus insulin regimen with twice-daily basal insulin. Basal insulin was switched to once-daily injection of insulin degludec with 10% dose reduction. HbA1c and fasting plasma glucose (FPG) were measured before and 12 weeks after switching. The frequency of hypoglycemic episodes, standard deviation (SD) of blood glucose, and mean of daily difference (MODD) were evaluated by continuous glucose monitoring (CGM) before and 4 weeks after switching. HbA1c and FPG before and 12 weeks after switching were comparable (HbA1c 8.5 ± 1.4 versus 8.7 ± 1.6%,P=0.28; FPG 203.2 ± 81.2 versus 206.5 ± 122.4 mg/dL,P=0.91). The frequency of hypoglycemia during nighttime was not significantly different at 4 weeks after switching (14.4 ± 17.0 versus 11.1 ± 15.0%,P=0.45). In addition, SD and MODD before and 4 weeks after switching were also comparable. In conclusion, glycemic control under once-daily insulin degludec injection was almost comparable to that under twice-daily basal insulin injections in Japanese type 1 diabetes patients. This study was registered with ID:UMIN000010474.

scholarly journals Insulin degludec: The new standard long acting insulin analogue for people with type 1 diabetes? [Letter to the Editor]

2016 ◽  
Vol 63 (4) ◽  
pp. 411-412 ◽  
Author(s):  
Agustín Ángel Merchante-Alfaro ◽  
Susana Pérez-Naranjo ◽  
Pablo Abellán-Galiana ◽  
Olalla Rubio-Puchol
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Analogue ◽  
Insulin Degludec ◽  
Acting Insulin ◽  
Letter To The Editor ◽  
Long Acting

Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes. A systematic review and meta-analysis

2011 ◽  
Vol 121 (7-8) ◽  
pp. 237-246 ◽  
Author(s):  
Agnieszka Szypowska ◽  
Dominik Golicki ◽  
Lidia Groele ◽  
Ewa Pańkowska
Keyword(s):  
Systematic Review ◽  
Type 1 Diabetes ◽  
Insulin Analogue ◽  
Meta Analysis ◽  
Nph Insulin ◽  
Acting Insulin ◽  
Long Acting
Sign in / Sign up

Export Citation Format

Share Document